CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
Open Access
- 31 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2), e000860
- https://doi.org/10.1136/jitc-2020-000860
Abstract
Background Regulatory T cells (T-regs) contribute to an immunosuppressive tumor microenvironment. They play an important role in the establishment and progression of tumors with high T(regs)infiltration and present a major obstacle to tumor eradication by immunotherapies. Numerous strategies have been attempted to deplete or block T-regs, although their success has been limited. Methods A CD25-targeted, pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) was investigated for its ability to deplete T(regs)and induce antitumor immunity. Antitumor activity of CD25-ADC either alone or in combination with an anti-programmed cell death protein 1 (PD-1) antibody was evaluated in CD25-negative syngeneic models that exhibit tumor infiltration of CD25-expressing T-regs, and its pharmacodynamics and pharmacokinetics were assessed. Results Single low doses of CD25-ADC resulted in potent and durable antitumor activity in established syngeneic solid tumor models and the combination of a suboptimal dose was synergistic with PD-1 blockade. Tumor eradication by the CD25-targeted ADC was CD8+ T cell-dependent and CD25-ADC induced protective immunity. Importantly, while CD25-ADC mediated a significant and sustained intratumoral T(regs)depletion, accompanied by a concomitant increase in the number of activated and proliferating tumor-infiltrating CD8+ T effector cells, systemic T(regs)depletion was transient, alleviating concerns of potential autoimmune side effects. Conclusions This study shows that a PBD dimer-based, CD25-targeted ADC is able to deplete T(regs)and eradicate established tumors via antitumor immunity. This represents a novel approach to efficiently deplete T(regs)via a very potent DNA damaging toxin known to induce immunogenic cell death. Moreover, this study provides proof of concept for a completely new application of ADCs as immunotherapeutic agents, as the main mode of action relies on the ADC directly targeting immune cells, rather than tumor cells. These strong preclinical data warrant the clinical evaluation of camidanlumab tesirine (ADCT-301), a PBD-based ADC targeting human CD25, either alone or in combination with checkpoint inhibitors in solid tumors with known T(regs)infiltration. A phase I trial (NCT03621982) of camidanlumab tesirine in patients with selected advanced solid tumors is ongoing.Funding Information
- ADC Therapeutics
This publication has 30 references indexed in Scilit:
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological MalignanciesMolecular Cancer Therapeutics, 2016
- Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapiesAnnals of Oncology, 2016
- Antibody–drug conjugates as novel anti-cancer chemotherapeuticsBioscience Reports, 2015
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanomaThe Journal of Experimental Medicine, 2013
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- Assessing Interactions for Fixed-Dose Drug Combinations in Tumor Xenograft StudiesJournal of Biopharmaceutical Statistics, 2012
- The role of interleukin-2 during homeostasis and activation of the immune systemNature Reviews Immunology, 2012
- Targeting regulatory T cellsTargeted Oncology, 2012
- T‐cell tolerance and the multi‐functional role of IL‐2R signaling in T‐regulatory cellsImmunological Reviews, 2011
- High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61.The Journal of Immunology, 1985